Associated Papers
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.
Bittner M et al.
International Journal of Molecular Sciences, 2026
41751910 (PubMed )
Supplement: ijms-27-01774-s001.zip › Tables_Suppl_Carey_MS_2025_Revised_20260129.xlsx › Suppl_Table_5
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R et al.
Cancer Research, 2021
Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target.
Fernandez ML et al.
Cancer Cell International, 2019
Clonal analyses of refractory testicular germ cell tumors.
Barrett MT et al.
Plos One, 2019
Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment.
Portet S et al.
Neuro-oncology Advances, 0
Select a paper to view details